Response to encainide of refractory ventricular tachycardia: clinical application of assays for parent drug and metabolites
- PMID: 6182414
- DOI: 10.1097/00005344-198209000-00018
Response to encainide of refractory ventricular tachycardia: clinical application of assays for parent drug and metabolites
Abstract
To assess the response to encainide in patients with malignant arrhythmias, we treated 22 patients with recurrent ventricular tachycardia (VT) or fibrillation (VF) refractory to an average of 5.7 drugs. Thirteen patients (59%) showed a favorable in-hospital response, and 11 of 22 (50%) maintained a favorable antiarrhythmic response during a median follow-up of 13.5 months (range 0.3--25.5). Encainide was well tolerated. Six (46%) of 13 patients responded to intravenous encainide with suppression of VT by programmed ventricular stimulation or continuous monitoring; oral encainide has maintained arrhythmia control. In six of seven others, cycle length of VT was lengthened. Initial therapy with oral drug yielded five complete and two partial responses, assessed by monitoring, among nine other patients. Of three outpatient failures, only one was an inpatient responder. Proarrhythmic responses were also noted and included spontaneous increases in ectopy (three patients), easier induction of VT spontaneously or at programmed stimulation (three patients), facilitation of exercise VT (one patient), and syncope due to VT/VF (one patient). After intravenous therapy, plasma encainide concentration averaged 773 ng/ml (range 476--1,279, n = 4), with low or negligible metabolites. During chronic oral therapy, encainide concentrations were low and variable, averaging 67.5 ng/ml (less than 10--585; n = 23, 10 patients); metabolite levels were higher and less variable: O-demethyl encainide, mean 198 ng/ml (61--882); 3-methoxy-o-demethyl encainide, mean 128 ng/ml (39--379). Active metabolites(s) may thus be more important than parent drug during chronic therapy. In summary, encainide may provide successful therapy in approximately half of patients with malignant, refractory ventricular arrhythmias. Inpatient response predicts outpatient results. Encainide, like other antiarrhythmics, has proarrhythmic potential, suggesting a carefully monitored initial approach.
Similar articles
-
Antiarrhythmic efficacy, clinical electrophysiology, and pharmacokinetics of 3-methoxy-O-desmethyl encainide (MODE) in patients with inducible ventricular tachycardia or fibrillation.Circulation. 1989 Nov;80(5):1247-58. doi: 10.1161/01.cir.80.5.1247. Circulation. 1989. PMID: 2805262
-
Electrophysiologic and electrocardiographic effects, efficacy and safety of encainide in malignant ventricular arrhythmias associated with coronary artery disease.Am J Cardiol. 1990 Oct 15;66(12):947-53. doi: 10.1016/0002-9149(90)90931-p. Am J Cardiol. 1990. PMID: 2121017
-
Encainide in lethal ventricular arrhythmias evaluated by electrophysiologic testing and decrease in symptoms.Am J Cardiol. 1986 Aug 29;58(5):83C-86C. doi: 10.1016/0002-9149(86)90109-8. Am J Cardiol. 1986. PMID: 3092624 Review.
-
Efficacy and safety of class IC antiarrhythmic agents for the treatment of coexisting supraventricular and ventricular tachycardia.Am J Cardiol. 1988 Aug 25;62(6):44D-55D. doi: 10.1016/0002-9149(88)90507-3. Am J Cardiol. 1988. PMID: 3136636 Clinical Trial.
-
Encainide: a new antiarrhythmic agent.Drug Intell Clin Pharm. 1986 Jan;20(1):9-13. doi: 10.1177/106002808602000101. Drug Intell Clin Pharm. 1986. PMID: 3080301 Review.
Cited by
-
Encainide. A review of its pharmacological properties and therapeutic efficacy.Drugs. 1987 Nov;34(5):519-38. doi: 10.2165/00003495-198734050-00002. Drugs. 1987. PMID: 3121275 Review.
-
Clinical pharmacokinetics of encainide.Clin Pharmacokinet. 1988 Mar;14(3):141-7. doi: 10.2165/00003088-198814030-00002. Clin Pharmacokinet. 1988. PMID: 3131058 Review.
-
Effects of encainide on the inducibility of ventricular arrhythmia in normal anesthetized dogs.J Tongji Med Univ. 1986;6(1):60-6. doi: 10.1007/BF02911621. J Tongji Med Univ. 1986. PMID: 3086567 No abstract available.
-
Encainide and its metabolites. Comparative effects in man on ventricular arrhythmia and electrocardiographic intervals.J Clin Invest. 1984 Feb;73(2):539-47. doi: 10.1172/JCI111241. J Clin Invest. 1984. PMID: 6421879 Free PMC article.
-
Encainide.Cardiovasc Drugs Ther. 1989 Oct;3(5):691-710. doi: 10.1007/BF01857621. Cardiovasc Drugs Ther. 1989. PMID: 2518680 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical